1/28/2010

Spectrum Pharmaceuticals decided to abandon development of ozarelix, its experimental treatment for benign prostatic hypertrophy, after the drug fared poorly in a midstage clinical trial. The move is expected to save Spectrum more than $40 million.

Full Story:
Reuters

Related Summaries